We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MOR MorphoSys AG

0.00 (0.0%)
Pre Market
Last Updated: 04:21:51
Delayed by 15 minutes


Draw Mode:

Volume 50
Bid Price 6.77
Ask Price 6.81
News -
Company Name Stock Ticker Symbol Market Type
MorphoSys AG MOR NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 6.85 04:21:51
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume
1 50 -
Last Trade Time Type Quantity Stock Price Currency
04:13:13 50  6.80 USD

MorphoSys AG Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
854.02M 34.16M - 278.27M -151.06M -4.42 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News MorphoSys

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MOR Message Board. Create One! See More Posts on MOR Message Board See More Message Board Posts

MOR Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |